BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang HW, Zhao X, Xu RX, Guo YL, Zhu CG, Wu NQ, Cui CJ, Dong Q, Li JJ. Relationship between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and Estimated Glomerular Filtration Rate in the General Chinese Population. Cardiorenal Med 2018;8:311-20. [PMID: 30121647 DOI: 10.1159/000490766] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Kajingulu FM, Lepira FB, Nkodila AN, Makulo JR, Mokoli VM, Ekulu PM, Bukabau JB, Nlandu YM, Longo AL, Nseka NM, Labriola L, Sumaili EK. Circulating Proprotein Convertase Subtilisin/Kexin type 9 level independently predicts incident cardiovascular events and all-cause mortality in hemodialysis black Africans patients. BMC Nephrol 2022;23:123. [PMID: 35354429 DOI: 10.1186/s12882-022-02748-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Didas N, Thitisopee W, Porntadavity S, Jeenduang N. Arylesterase activity but not PCSK9 levels is associated with chronic kidney disease in type 2 diabetes. Int Urol Nephrol 2020;52:1725-32. [PMID: 32661629 DOI: 10.1007/s11255-020-02547-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Del Vecchio L, Baragetti I, Locatelli F. New agents to reduce cholesterol levels: implications for nephrologists. Nephrology Dialysis Transplantation 2019. [DOI: 10.1093/ndt/gfz013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]